Document type: Toolkit Practice area: Intellectual Property — Patents Jurisdiction: United States (federal) Last reviewed: 5 September 2026

1. Orange Book and exclusivity analysis worksheet

The first document in any Hatch-Waxman matter. The answer it produces — the earliest lawful entry date — drives everything.

PRODUCT: __________  NDA No.: __________  Sponsor: __________
Prepared by: __________  Date: __________

LISTED PATENTS
| Patent | Type (compound / formulation / method / device) |
  Expiry | PTE applied? | Extended expiry | Use code |
  Listing date | Certification decision |

UNLISTED PATENTS IDENTIFIED
| Patent | Subject matter | Expiry | Assertable outside this
  framework? |

REGULATORY EXCLUSIVITIES
NCE (5 yr; 4 yr for Paragraph IV filing): expires ________
New clinical investigation (3 yr): expires ________ [scope: __]
Orphan (7 yr): expires ________ [indication: __]
Pediatric (+6 months, additive to all): ________
Other: ________

PATENT TERM EXTENSION
Patent extended: ________  Original expiry: ________
Extension granted: ______ days  Extended expiry: ________
Basis of calculation: ________________________________

FIRST ELIGIBLE FILING DATE: ________
EARLIEST POSSIBLE ENTRY (no litigation): ________
EARLIEST ENTRY IF ALL PARAGRAPH IV CHALLENGES SUCCEED: ________

**THE OPERATIVE DATE IS THE LATEST OF ALL PATENTS AND ALL
EXCLUSIVITIES — NOT THE LAST PATENT TO EXPIRE.**

180-DAY EXCLUSIVITY MODEL (generic side)
Expected first filers: ________  Shared? [ ] Yes [ ] No
Assumed authorized generic launch: [ ] Day 1 [ ] Later [ ] None
Modeled exclusivity value: $________
Forfeiture risks: ______________________________

Drafting notes.

The bolded line is the point of the worksheet. Business teams consistently model the last patent expiry and are then surprised by pediatric exclusivity or an orphan designation adding months or years.

Model the authorized generic at day one. It is foreseeable, it is lawful, and assuming otherwise overstates exclusivity value by roughly half.

Include unlisted patents. They cannot produce a stay, but they can produce a separate infringement action at launch, which is a different and sometimes worse problem.

2. Certification decision matrix

CERTIFICATION DECISIONS — ANDA for __________

| Patent | Claim type | Our position | Strength (1-5) |
  Certification | Rationale |
| '123 | Compound | Expires 2031; no viable challenge | — |
  Para III | Concede; approval at expiry |
| '456 | Formulation | Our excipient ratio is outside the
  claimed range; claims also obvious over X + Y | 4 |
  Para IV | Controls the date; strong non-infringement |
| '789 | Method of use (indication B) | Use code appears
  broader than the claims | 3 | Section viii | Carve out
  indication B; monitor Caraco counterclaim option |
| '012 | Device component | Improperly listed? | 2 |
  Para IV + delisting counterclaim | Preserve the challenge |

STRATEGIC SUMMARY
Patents controlling the entry date: ______________
Patents conceded: ______________
Litigation scope this produces: ______ patents, ______ likely
issues
First-filer status preserved? [ ] Yes [ ] No

Drafting notes.

Certifying Paragraph IV to everything is the most common and most expensive generic error. Each Paragraph IV is a potential patent case. Challenge what controls the date; concede the rest.

The "controls the date" column is the analysis. A patent expiring in 2031 does not matter if another patent runs to 2034 and cannot be challenged.

Record the rationale contemporaneously. Certification decisions get scrutinized in litigation and, occasionally, in antitrust proceedings.

3. Paragraph IV notice letter

[Date — SEND BY A METHOD THAT DOCUMENTS RECEIPT]

[NDA Holder]                 [Patent Owner, if different]

Re: Notice of Certification under 21 U.S.C.
    § 355(j)(2)(B) — ANDA No. [___] for [Drug Name and
    Strength]

Dear Sir or Madam:

[Applicant] has submitted to FDA an Abbreviated New Drug
Application seeking approval to engage in the commercial
manufacture, use, and sale of [drug, strength, dosage form]
before the expiration of the following patents listed in the
Orange Book for [Reference Listed Drug]:

  U.S. Patent No. [___]  U.S. Patent No. [___]

For each, Applicant has certified under 21 U.S.C.
§ 355(j)(2)(A)(vii)(IV) that the patent is invalid,
unenforceable, or will not be infringed by the manufacture,
use, or sale of the drug product described in the ANDA.

This letter provides the detailed statement of the factual and
legal basis for that opinion.

I.   THE ANDA PRODUCT
     [Describe the product at the level needed to support the
     non-infringement analysis: active ingredient, strength,
     dosage form, and the formulation characteristics relevant
     to the asserted claims.]

II.  U.S. PATENT NO. [___]
     A. The claims
     B. Non-infringement
        [Claim-by-claim. For each independent claim, identify
        the limitation not met and explain why, by reference to
        the ANDA product.]
     C. Invalidity
        [Ground by ground, with the art applied claim by claim.]

III. U.S. PATENT NO. [___]
     [Same structure.]

IV.  OFFER OF CONFIDENTIAL ACCESS
     Applicant offers confidential access to the ANDA under
     [21 U.S.C. § 355(j)(5)(C)(i)(III)] on the following terms:
     [reasonable terms: outside counsel and retained experts,
     no involvement in patent prosecution for the relevant
     technology for a defined period, no use for any purpose
     other than determining whether to bring an action, return
     or destruction at conclusion].

Please direct any communications to the undersigned.

Very truly yours,

Drafting notes.

Send by a method that documents receipt. The 45-day window and the 30-month stay both run from receipt, and the date is litigated when it is close.

Section II.B is the heart. A conclusory assertion of non-infringement is not a "detailed statement," and inadequate notice has been litigated.

Every position you may later assert should appear here. Contentions that surface for the first time in litigation draw arguments that they are untimely or that the notice was defective.

Section IV's terms should be reasonable. An unreasonable offer of confidential access delays the brand's analysis, invites a motion, and looks obstructive — and it does not prevent the suit, because the brand will file protectively regardless.

Resist length for its own sake. Two well-supported grounds are more persuasive than fifteen thin ones, and a short letter signals confidence.

4. Confidential access agreement — key terms

CONFIDENTIAL ACCESS AGREEMENT — ANDA No. [___]

1. PURPOSE. The ANDA and information derived from it are
provided solely to permit [NDA Holder] and its counsel to
determine whether to bring an action under 35 U.S.C.
§ 271(e)(2), and for use in any such action.

2. PERMITTED RECIPIENTS. Outside litigation counsel; retained
experts and consultants who execute the attached
acknowledgment; and necessary support personnel. NOT in-house
counsel or business personnel, except [defined exceptions with
individual approval].

3. PROSECUTION BAR. No person receiving Applicant's
confidential information shall, for [two] years following
conclusion of this matter, participate in the prosecution of
any patent application relating to [defined technology field],
including drafting or amending claims.

4. USE RESTRICTION. The information shall not be used for any
business, competitive, or regulatory purpose.

5. DESIGNATION. Applicant may designate materials
"CONFIDENTIAL" or "HIGHLY CONFIDENTIAL — OUTSIDE COUNSEL AND
EXPERTS ONLY." The manufacturing process and formulation
details are presumptively the latter.

6. FILING. Any filing containing designated material shall be
made under seal, subject to the court's sealing procedures.

7. RETURN OR DESTRUCTION. Within [30] days of conclusion, all
copies shall be returned or destroyed, except one archival
copy retained by outside counsel.

8. NO WAIVER. Production under this Agreement does not waive
any privilege or trade secret protection.

9. TIMING. Applicant shall produce the ANDA within [5] business
days of execution.

Drafting notes.

Paragraph 9 matters more than it looks. The brand has 45 days total. Every day between notice and production is a day not spent on analysis, and a five-business-day commitment is reasonable and should be insisted on.

The prosecution bar is genuinely important on both sides. The lawyers who read an ANDA formulation should not be drafting claims in the same space, and the same is true in reverse for the brand's prosecution files.

Paragraph 2's exclusion of in-house counsel is standard and is negotiable for specific individuals with a written undertaking, particularly where a company has no outside regulatory counsel.

5. Brand 45-day tracker

PARAGRAPH IV NOTICE — 45-DAY TRACKER

Notice received (DATE AND METHOD): ______________________
  ** 45-day deadline: __________ **
  ** 30-month stay expires: __________ **
Applicant: __________  ANDA No.: __________
Patents certified to: ______________________
Section viii statement on: ______________________
First filer? [ ] Yes [ ] No [ ] Unknown

DAY  TASK                                    OWNER   DONE
 1   Log receipt; distribute; open matter    ____    [ ]
 1   Preserve applicant's public materials   ____    [ ]
 2   Confidential access agreement drafted   ____    [ ]
 5   Agreement executed                      ____    [ ]
10   ANDA received                           ____    [ ]
12   Formulation review assigned             ____    [ ]
12   Analytical review assigned              ____    [ ]
12   Regulatory review assigned              ____    [ ]
20   Preliminary infringement assessment     ____    [ ]
25   Invalidity contentions assessed         ____    [ ]
25   Induced infringement assessment (§ viii)____    [ ]
30   Venue decision                          ____    [ ]
32   Assertion decision (which patents)      ____    [ ]
35   Complaint drafted                       ____    [ ]
40   Client approval                         ____    [ ]
**44 COMPLAINT FILED**                       ____    [ ]
45   Confirm docket entry and service plan   ____    [ ]

PARALLEL FILERS
Other notices received: ______________________
Coordination plan: ______________________

Drafting notes.

Day 1's preservation task is the one most often missed and the one that cannot be recovered. Websites change, investor decks are replaced, press releases are archived. Capture them with dated preservation on day one.

Day 5's execution deadline drives everything. A brand that spends three weeks negotiating confidential access has twenty days to analyze an ANDA.

Filing on day 44 rather than day 45 leaves a day for a filing problem. There is no relief for missing this deadline.

6. ANDA complaint outline

COMPLAINT FOR PATENT INFRINGEMENT UNDER 35 U.S.C. § 271(e)(2)

I.   NATURE OF THE ACTION
     This is an action under the Hatch-Waxman Act arising from
     Defendant's submission of ANDA No. ___ seeking approval to
     market a generic version of Plaintiff's [Drug] before the
     expiration of the patents-in-suit.

II.  PARTIES
III. JURISDICTION AND VENUE
     28 U.S.C. §§ 1331, 1338(a); personal jurisdiction based on
     [the ANDA submission directed to the United States, the
     intent to market nationwide, and Defendant's contacts with
     this District].

IV.  THE PATENTS-IN-SUIT
     [For each: number, issue date, title, ownership, Orange
     Book listing, and any patent term extension.]

V.   THE APPROVED PRODUCT
     [NDA number, approval date, indications, exclusivities.]

VI.  DEFENDANT'S ANDA AND NOTICE
     [ANDA number; the certifications made; the date notice was
     received — PLEAD THIS DATE PRECISELY; that this action is
     brought within 45 days of receipt.]

VII. COUNT I — INFRINGEMENT OF THE '___ PATENT UNDER § 271(e)(2)
     [The submission of the ANDA for the purpose of obtaining
     approval to market before expiration is an act of
     infringement. Identify the claims and, at the level the
     information permits, why the ANDA product falls within
     them.]

VIII.COUNT II — INDUCED INFRINGEMENT OF THE '___ PATENT
     [Where a section viii carve-out is at issue: the proposed
     label, the specific retained content, the applicant's
     public statements, and the allegation that the applicant
     will encourage the patented use.]

IX.  COUNT III — DECLARATORY JUDGMENT
     [Where appropriate, as to future commercial manufacture.]

X.   PRAYER FOR RELIEF
     A. Judgment that submission of the ANDA infringes;
     B. An order under 35 U.S.C. § 271(e)(4)(A) that the
        effective date of any approval be no earlier than the
        expiration of the patents-in-suit;
     C. A permanent injunction under § 271(e)(4)(B);
     D. Damages under § 271(e)(4)(C) IF Defendant engages in
        commercial manufacture, use, or sale;
     E. A declaration that this is an exceptional case under
        35 U.S.C. § 285;
     F. Costs and such other relief as is just.

Drafting notes.

Paragraph VI's notice date is the most important factual allegation in the complaint. Plead it precisely; the stay depends on it.

The prayer's structure reflects the unusual remedy. The primary relief is a date, not money. Damages are pleaded conditionally because § 271(e)(4) permits them only if there has been commercial manufacture, use, or sale.

Do not over-plead the infringement specifics. The complaint is filed on incomplete information and everyone knows it. Specific allegations that turn out to be wrong are quoted back at you.

Count II should be pleaded only where the record supports it. A boilerplate induced infringement count against a lawful carve-out invites a motion and a fee argument.

7. Section viii carve-out review and launch scrub

CARVE-OUT COMPLIANCE REVIEW — [Product]
Carved-out indication: __________
Patent carved around: __________  Use code: __________
Reviewed by: __________  Date: __________

PART A — THE LABEL
[ ] Indications and Usage: carved-out indication removed
[ ] Dosage and Administration: any dosing regimen unique to
    the carved-out indication removed
[ ] Dosage Forms and Strengths: any strength used only for the
    carved-out indication reviewed
[ ] Contraindications / Warnings / Precautions: references
    removed unless required for the retained indication
[ ] Adverse Reactions: study data specific to the carved-out
    indication removed
[ ] Clinical Pharmacology: content specific to the carved-out
    indication removed
[ ] Clinical Studies: trials supporting only the carved-out
    indication removed
[ ] Patient labeling / Medication Guide: reviewed
FINDINGS: ______________________________________

PART B — COMMERCIAL MATERIALS
[ ] Product catalog / monograph
[ ] Website product pages
[ ] Press releases — **check for "generic version of [brand]"**
[ ] Investor presentations and earnings scripts
[ ] Analyst Q&A preparation
[ ] Sales training and detailing materials
[ ] Payer / formulary submissions and TE statements
[ ] Compendia entries within our influence
[ ] Cartons, inserts, and artwork
[ ] Distributor and wholesaler communications
FINDINGS: ______________________________________

PART C — TRAINING
[ ] Commercial team briefed on what cannot be said
[ ] One-paragraph written guidance issued
[ ] Approval process for new materials established

CONCLUSION
[ ] Carve-out compliant; approved for launch
[ ] Remediation required: ______________________

Drafting notes.

Part A's dosing item is where the litigated disputes concentrate. A dosing table retained because it also applies to the kept indication is defensible; one that applies only to the carved-out indication is the brand's exhibit.

Part B's press release item deserves the emphasis. "A generic version of [brand]" is a single sentence written by someone in investor relations, and it has been the centerpiece of induced infringement cases.

Part C is what prevents recurrence. The label is reviewed once; the marketing materials are created continuously by people who have never heard of section viii.

Keep the completed form. It is the evidence that counsel reviewed the launch.

8. Induced infringement evidence log (brand side)

INDUCED INFRINGEMENT EVIDENCE — [Generic] / [Product]

LABEL EVIDENCE
| Section | Retained content | Relevant to carved-out use? |
  Also relevant to retained use? | Strength |

PUBLIC STATEMENTS
| Date | Source | Statement | Capture method | Still available? |
| __ | Press release | "generic version of [brand]" | PDF +
  Wayback | [ ] |
| __ | Investor deck slide 12 | "$X billion market" [the
  carved-out indication's market] | PDF | [ ] |
| __ | Earnings call | [quote] | Transcript | [ ] |

MARKETING MATERIALS (from discovery)
| Bates | Description | Content at issue |

MARKET EVIDENCE
[ ] Prescription data by indication
[ ] Substitution rates
[ ] Physician or pharmacist testimony
[ ] Formulary placement and payer communications

ASSESSMENT
Strongest evidence: ______________________________
Weakest link: ____________________________________
Realistic assessment: ____________________________

Drafting notes.

The "still available" column is why this log exists. Capture on day one with dated preservation; a screenshot without a date is worth much less than an archived capture.

The "also relevant to retained use" column keeps you honest. Content that serves both indications is weak evidence, and building a case on it invites a fee motion.

Be realistic in the assessment. A case built on one ambiguous investor statement is a weak case, and the Federal Circuit's decisions in this area have gone more than one way.

9. IPR estoppel analysis

IPR DECISION MEMORANDUM — U.S. Patent No. __________

1. THE ART
   Printed publications (usable in IPR): ______________
   Prior public use / on-sale (COURT ONLY): ______________
   System prior art (COURT ONLY): ______________
   Strength of the printed-publication case alone: ______

2. TIMING
   District court trial date: ______
   Petition filing date if filed now: ______
   Institution decision expected: ______
   Statutory final written decision deadline: ______
   Is the trial date BEFORE the Board's deadline? [ ] Yes [ ] No
   Discretionary denial risk: [ ] High [ ] Medium [ ] Low

3. ESTOPPEL EXPOSURE — 35 U.S.C. § 315(e)
   Grounds we would raise in the IPR: ______________
   Grounds we "reasonably could have raised": ______________
   District court invalidity defenses LOST if estopped:
   ______________________________________________
   Do we retain any invalidity defense in court? [ ] Yes [ ] No
   [If no, this is a very serious cost.]

4. PRIMARY DEFENSE
   Is our primary defense non-infringement? [ ] Yes [ ] No
   [The Board cannot decide it. If yes, weigh heavily against.]

5. OTHER
   IPR does not affect the 30-month stay or FDA approval.
   Eligibility unavailable in IPR (35 U.S.C. § 311).
   Claim construction consistency plan: ______________

6. RECOMMENDATION
   [ ] File   [ ] Do not file   [ ] File on [subset of patents]
   Reasoning: ______________________________________

Drafting notes.

Section 3's last question is the decision. A generic that would be left with no invalidity defense in the forum that decides infringement has traded a great deal for a second forum.

Section 2's timing question drives discretionary denial. ANDA cases in Delaware and New Jersey frequently have trial dates that precede the Board's deadline.

Section 5's consistency plan is not optional. Assign one person to review every filing in both forums.

10. At-risk launch memorandum

PRIVILEGED — BOARD MATERIAL
AT-RISK LAUNCH ANALYSIS — [Product]
Prepared by: __________  Date: __________

1. POSTURE
   District court judgment: [outcome, date]
   Appeal filed by: __________  Expected decision: __________
   FDA approval status: __________
   180-day exclusivity status: __________

2. UPSIDE
   Expected net revenue during the appeal period: $________
   Basis: [price × share × months, with assumptions]
   Value of establishing market position: $________
   Value of the exclusivity period if used now: $________

3. DOWNSIDE
   Probability of reversal (appellate counsel's written
   assessment attached): ______%
   **Damages if reversed: the BRAND's lost profits**, not a
   royalty — 35 U.S.C. § 271(e)(4)(C): $________
   [Brand price × units we take × margin × months]
   Enhanced damages exposure (willfulness): $________
   Attorney's fees under 35 U.S.C. § 285: $________
   Injunction / recall / customer disruption: $________
   TOTAL DOWNSIDE: $________

4. EXPECTED VALUE
   (1 − p) × upside − p × downside = $________

5. NON-FINANCIAL FACTORS
   Insurance coverage: ______________________
   Customer and distributor commitments if withdrawn: ______
   Reputational and regulatory consequences: ______________
   Competitive position if we wait: ______________

6. RECOMMENDATION AND APPROVALS
   Recommendation: ______________________
   General Counsel: __________  CEO: __________
   Board approval date: __________

Drafting notes.

Section 3's damages line is the whole memorandum. The brand's lost profits on a branded product can be many multiples of the generic's revenue, because the brand loses high-margin sales to a low-priced substitute. Companies that model their own revenue as the exposure understate it dramatically.

Attach appellate counsel's written assessment. A board approving this decision needs an independent probability, not the trial team's.

This is a board decision. Document the approval.

11. Settlement term sheet

SETTLEMENT TERM SHEET — [Brand] / [Generic]
[Product] — ANDA No. __________

1. ENTRY DATE. Generic may commence commercial marketing on
   __________ (the "Entry Date").

2. LICENSE. Effective on the Entry Date, Brand grants a
   non-exclusive, royalty-free license under the patents-in-suit
   for the ANDA product in the United States.

3. ACCELERATION. The Entry Date accelerates to the earliest of:
   (a) the date any third party launches a generic version of
       the Product;
   (b) the date a court holds all patents-in-suit invalid,
       unenforceable, or not infringed in a final judgment;
   (c) the date Brand launches or authorizes an authorized
       generic [if AG is not otherwise permitted];
   (d) [other defined events].

4. MOST FAVORED ENTRY. If Brand grants any other ANDA filer an
   entry date earlier than the Entry Date, Generic's Entry Date
   accelerates to that date.

5. AUTHORIZED GENERIC. [Choose one, and price it:]
   (a) Brand may launch an AG at any time; OR
   (b) Brand shall not launch or authorize an AG until
       __________; OR
   (c) Brand shall not launch or authorize an AG during
       Generic's 180-day exclusivity period.
   **NOTE: (b) and (c) are CONSIDERATION flowing to Generic and
   must be analyzed under FTC v. Actavis.**

6. NO PAYMENT. [If true:] No payment or other value flows from
   Brand to Generic under this Agreement.
   [If not true:] Consideration flowing to Generic:
   __________ — see the Antitrust Justification Memorandum.

7. DISMISSAL. The action is dismissed [with/without] prejudice;
   Generic's certifications are [maintained / amended].

8. REGULATORY. Generic shall not amend its ANDA to seek
   approval for [the carved-out indication] before __________.

9. REPORTING. The parties shall file the agreement with the FTC
   and DOJ as required by 21 U.S.C. § 355 note (Medicare
   Modernization Act § 1112).

10. CONFIDENTIALITY. [Subject to the reporting obligation and
    to securities disclosure requirements.]

Drafting notes.

Paragraph 5 is where the money is and where the antitrust risk is. A no-authorized-generic commitment is worth a great deal to a first filer — it can double the value of the 180-day period — and it is consideration for FTC v. Actavis purposes. Analyze it as such.

Paragraph 4's most-favored-entry provision is standard and it means the first settlement effectively sets the entry date for everyone. Model the whole board before signing the first deal.

Paragraph 9 is mandatory. Every settlement is reported and reviewed.

Paragraph 3(b) matters to a subsequent filer whose entry depends on the first filer's exclusivity, and it should be drafted with the forfeiture provisions in view.

12. Antitrust justification memorandum

Prepared contemporaneously with structuring, not afterward.

PRIVILEGED — ANTITRUST ANALYSIS OF PROPOSED SETTLEMENT
[Brand] / [Generic] — [Product]
Prepared by: __________  Date: __________

1. THE SETTLEMENT
   Entry date: __________  (patent expiry: __________)
   Years before expiry: ______

2. CONSIDERATION FLOWING TO GENERIC
   [ ] None
   [ ] Cash: $________
   [ ] No-AG commitment [value estimate: $________]
   [ ] Supply agreement [terms; independent value analysis]
   [ ] License to another product [terms; value]
   [ ] Development or co-promotion arrangement [terms; value]
   [ ] Other: ______________
   TOTAL ESTIMATED VALUE: $________

3. JUSTIFICATIONS
   A. Avoided litigation costs
      Brand's projected remaining litigation cost: $________
      [Attach the actual budget. This is the justification the
      Supreme Court identified, and it must be documented with
      real figures.]
   B. Independent value of any side deal
      [For each: what is being purchased, what an arm's-length
      price would be, how the price was determined, and whether
      Brand would have entered the arrangement absent the
      litigation.]
   C. Other consideration
      ______________________________________

4. ANALYSIS UNDER FTC v. ACTAVIS
   Is the payment "large"? ______
   Is it "unjustified" after accounting for §3? ______
   Does the size suggest Brand's own assessment of patent
   weakness? ______
   Is the entry date meaningfully earlier than expiry? ______
   Competitive effects assessment: ______________________

5. REPORTING
   FTC/DOJ filing prepared: [ ] Yes  Date: ______

6. CONCLUSION
   [ ] No reverse payment concern
   [ ] Payment justified by documented litigation costs and/or
       independent value
   [ ] Structure should be revised: ______________________

Drafting notes.

Section 3.A must attach real budget figures. A generic assertion that the payment reflects avoided litigation costs, unsupported by a budget prepared before the settlement, is not a justification.

Section 3.B is where side deals are tested. The question is whether Brand would have entered the arrangement absent the litigation and at what price. If nobody can answer that, the arrangement is a payment.

Prepare this before signing. A justification memorandum dated after an FTC inquiry is worth very little.

13. Quick reference — the clocks

Clock Period Runs from
Brand's window to sue 45 days Receipt of Paragraph IV notice
30-month stay 30 months Receipt of Paragraph IV notice
180-day exclusivity 180 days First filer's commercial marketing
NCE exclusivity 5 years (4 for Para IV filing) NDA approval
New clinical investigation exclusivity 3 years Approval of the application or supplement
Orphan exclusivity 7 years Approval for the designated indication
Pediatric exclusivity +6 months, additive Attaches to existing patents and exclusivities
IPR final written decision 12 months (extendable 6) Institution
Confidential access production Negotiated; ask for 5 business days Execution

Related documents

This toolkit is general information, not legal advice, and does not create an attorney-client relationship. Templates require adaptation by counsel to the product, the patents, and the applicable regulatory framework.